Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

Markets & Finance

First Albany Cuts Renovis to Neutral


From Standard & Poor's Equity Research

First Albany downgraded Renovis (RNVS) to neutral from buy, noting the research trials of the company's drug in development for treating ischemic stroke.

Analyst Lucy Lu says she has less confidence regarding the drug's efficacy, and doesn't feel comfortable having a buy recommendation on Renovis. Still, for the time being, she maintains her sales estimates.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus